版本:
中国

BRIEF-Fate Therapeutics reports Q1 loss per share of $0.24

May 15 Fate Therapeutics Inc

* Reports first quarter 2017 financial results

* Q1 revenue $1.0 million versus I/B/E/S view $947,000

* Qtrly net loss per common share, basic and diluted $0.24

* Research and development expenses were $8.0 million for Q1 of 2017 compared to $6.6 million for comparable period in 2016 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐